1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,019 | 0,022 | 08:54 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.10. | Genflow Biosciences PLC Announces Corporate Update | 403 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 09.10. | Genflow Biosciences - Corporate Update | 4 | RNS | ||
| GENFLOW BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 05.10. | Genflow Biosciences PLC Announces Presentation of Interim Results | 270 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 05.10. | Genflow Biosciences - Presentation of Interim Results | 1 | RNS | ||
| 29.09. | Genflow Biosciences PLC Announces Exercise of Warrants and Issue of Equity | 406 | ACCESS Newswire | THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018... ► Artikel lesen | |
| 29.09. | Genflow Biosciences - Exercise of Warrants and Issue of Equity | 2 | RNS | ||
| 29.09. | Genflow Biosciences GAAP EPS of -£0.08 | 3 | Seeking Alpha | ||
| 29.09. | Genflow Biosciences PLC Announces Half-year Financial Report | 281 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 29.09. | Genflow Biosciences - Half-year Financial Report | 1 | RNS | ||
| 08.09. | Genflow Biosciences reports positive anti-ageing dog trial results | 1 | Alliance News | ||
| 08.09. | Genflow: Gentherapie-Studie an Hunden erreicht primären Endpunkt | 2 | Investing.com Deutsch | ||
| 08.09. | Genflow meets primary endpoint in aged dog gene therapy trial | 2 | Investing.com | ||
| 08.09. | Genflow Biosciences PLC Announces Primary Endpoint in SLAB Clinical Trial Met | 332 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 08.09. | Genflow Biosciences - Primary Endpoint in SLAB Clinical Trial Met | 1 | RNS | ||
| 07.09. | Genflow Biosciences PLC Announces Appointment of Investor Relations Adviser | 253 | ACCESS Newswire | LONDON, UK / ACCESS Newswire / September 7, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), an emerging leader in the field of longevity research, today announces... ► Artikel lesen | |
| 07.09. | Genflow Biosciences - Appointment of Investor Relations Adviser | - | RNS | ||
| 03.08. | Genflow Biosciences PLC Announces Patent Update | 305 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 03.08. | Genflow Biosciences - Patent Update | 1 | RNS | ||
| 13.07. | Genflow meldet positive Studiendaten bei Hunden und sichert sich LNP-Partnerschaft | 1 | Investing.com Deutsch | ||
| 13.07. | Genflow reports positive dog trial data, secures LNP partnership | 1 | Investing.com |
1 2 3 Weiter >>
53 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CRISPR THERAPEUTICS | 44,495 | -1,05 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 19.10.2026 | Folgende Wertpapiere werden in den Handel an der Frankfurter Wertpapierbörse (FWB) aufgenommen.
1. US88025U1097 10X GENOMICS INC
2. NL0000852564 AALBERTS NV
3. SE0016589188 ELECTROLUX AB
4. SE0000115446... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,866 | -2,30 % | PacBio, Verily Health Ink Multi-Year Deal to Scale Multi-Read Genomic Data for Biomedical AI | ||
| DENALI THERAPEUTICS | 15,975 | -3,91 % | Vom Brainshuttle zur Rückenmarksflüssigkeit: Wie Roche, Denali und NurExone Wirkstoffe ins Nervensystem bringen | ||
| VOYAGER THERAPEUTICS | 1,760 | 0,00 % | Voyager Therapeutics ernennt Robin Swartz zur Präsidentin und regelt CEO-Nachfolge | ||
| BIOAGE LABS | 4,976 | +1,34 % | BioAge Labs-Aktie mit -77% - jetzt zuschlagen? | Die BioAge-Labs-Aktie ist seit ihrem Hoch im Juli dramatisch eingebrochen und notiert aktuell nur noch bei 6,29 US$. Der jüngste Abverkauf hat nun die im Chart markierte Kurslücke vollständig geschlossen.... ► Artikel lesen | |
| LINEAGE CELL THERAPEUTICS | 0,877 | +3,18 % | 3 Wege zurück zur Bewegung: Warum NervGen, Lineage Cell Therapeutics und NurExone Rückenmarksverletzungen völlig unterschiedlich angehen | ||
| BIOPHYTIS | 0,012 | 0,00 % | XFRA 6XB3: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| SERINA THERAPEUTICS | 1,450 | 0,00 % | Serina Therapeutics, Inc.: Serina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson's Disease and Advances to Cohort 2 | - Independent Safety Monitoring Committee recommends advancement to Cohort 2 following blinded review of Cohort 1 safety and tolerability data - - Pharmacokinetic observations at the lowest dose... ► Artikel lesen | |
| LONGEVERON | 1,450 | 0,00 % | Morning Market Movers: Aethlon Medical, CID HoldCo, Longeveron, Delixy See Big Swings | OTTAWA (dpa-AFX) - At 8:50 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| QIAGEN | 42,820 | -0,02 % | Finanzinvestor EQT will Qiagen für über 9 Milliarden Euro kaufen - Agentur | DJ Finanzinvestor EQT will Qiagen für über 9 Milliarden Euro kaufen - Agentur
DOW JONES--Der Finanzinvestor EQT will einem Agenturbericht zufolge den Diagnostikspezialisten Qiagen übernehmen. Wie... ► Artikel lesen | |
| DISC MEDICINE | 75,94 | -0,08 % | Jefferies raises Disc Medicine stock price target on drug opportunity | ||
| ENLIVEN THERAPEUTICS | 41,820 | 0,00 % | H.C. Wainwright hebt Kursziel für Enliven Therapeutics auf 73 $ an | ||
| CG ONCOLOGY | 62,24 | 0,00 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected... ► Artikel lesen | |
| TANGO THERAPEUTICS | 26,990 | +0,04 % | Tango Therapeutics (TNGX) Has Striking Pancreatic Cancer Data. How Much Is Priced In? | ||
| PRAXIS PRECISION MEDICINES | 256,86 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen |
GENFLOW BIOSCIENCES PLC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,020 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GENFLOW BIOSCIENCES PLC finden Sie auf Wallstreet Online.